Anti-depressant like activity of N-n-butyl-3-methoxyquinoxaline-2-carboxamide (6o) a 5-HT3 receptor antagonist

Indian Journal of Experimental Biology

Volumn 51, Issue 6, 2013, Pages 435-443

  Bhatt, Shvetank ^a   Mahesh, Radhakrishnan ^a   Devadoss, Thangaraj ^a   Jindal, Ankur ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

5 HT3 receptor antagonists; Head twitches; Olfactory bulbectomy; Reserpine induced hypothermia; Tail suspension test

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; N N BUTYLQUINOXALIN 2 CARBOXAMIDE; N-N-BUTYLQUINOXALIN-2-CARBOXAMIDE; PAROXETINE; QUINOXALINE DERIVATIVE; SEROTONIN 3 ANTAGONIST;

ANIMAL; ANIMAL BEHAVIOR; ANXIETY; ARTICLE; DEPRESSION; DRUG EFFECT; GUINEA PIG; MOTOR ACTIVITY; MOUSE; OLFACTORY BULB; RAT; SWIMMING; WISTAR RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANXIETY; BEHAVIOR, ANIMAL; DEPRESSION; FLUOXETINE; GUINEA PIGS; MICE; MOTOR ACTIVITY; OLFACTORY BULB; PAROXETINE; QUINOXALINES; RATS; RATS, WISTAR; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; SWIMMING;

MUS; RATTUS; RODENTIA;

EID: 84879599002     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Hoyer D, Hannon J P & Martin G R, Molecular, pharmacological and functional diversity of 5-HT receptors, Pharmacol Biochem Behavior, 71 (2002) 533.
2. Davies P A, Wang W, Hales T G, & Kirkness E F, A novel class of ligand gated ion channel is activated by Zn2+, J Biol Chem, 278 (2003) 712.
3. Connolly C N & Wafford K A, The Cys-loop superfamily of ligand-gated ion channels: the impact of receptor structure on function, Biochem Soc Trans, 32 (2004) 529.
4. Haus U, Spath M & Farber L, Spectrum of use and tolerability of 5-HT3 receptor Antagonists, Scand J Rheumatol, 119 (2004) 12.
5. Mahesh R, Perumal R V & Pandi P V, Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods, Pharmazie, 60 (2005) 83.
6. Bloom F E & Morales M, The central 5-HT3 receptor in CNS disorders, Neurochem Res, 23 (1998) 653.
7. Costall B & Naylor N J, 5-HT3 Receptors, Curr Drug Targets CNS and Neurological Disorders, 3 (2004) 27.
8. Kilpatrick G J, Jones B J & Tyers M B, Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding, Nature, 330 (1987) 746.
9. Barnes J M, Barnes N M, Costall B, Ironside J W & Naylor R J, Identification and characterisation of 5-hydroxytryptamine 3 recognition sites in human brain tissue, J Neurochem, 53 (1989) 1787.
10. Abi-Dargham A, Laruelle M, Wong D T, Robertson D W, Weinberger D & Kleinman J E, Pharmacological and regional characterization of [3H] LY278584 binding sites in human brain, J Neurochem, 60 (1993) 730.
11. Bufton K E, Steward L J, Barber P C & Barnes N, Distribution and characterization of the [3H] granisetronlabelled 5-HT3 receptor in the human forebrain, Neuropharmacology, 32 (1993) 1325.
12. Kelley S P, Bratt A M & Hodge C W, Targeted gene deletion of the 5-HT3A receptor subunit produces an anxiolytic phenotype in mice, Eur J Pharmacol, 461(2003) 19.
13. Bourin M, Redrobe J P & Baker G B, Pindolol does not act only on 5-HT1A receptors in augmenting antidepressant activity in the mouse forced swimming test, Psychopharmacology, 136 (1998) 226.
14. Haus U, Varga B, Stratz T, Spath M, & Muller W, Oral treatment of fibromyalgia with tropisetron given over 28 days: influence on functional andvegetative symptoms, psychometric parameters and pain, Scand J Rheumatol Suppl, 113 (2000) 55.
15. Faris P L, Eckert E D, Kim S W, Meller W H, Pardo J V & Goodale, R L,(2006). Evidence for a vagal pathophysiology for bulimia nervosa and the accompanying depressive symptoms, J Affect Disord, 92 (2006) 79.
16. Bourin M, Is it possible to predict the activity of a new antidepressant in animals with simple psychopharmacological tests, Fund Clin Pharmacol, 4 (1990) 49.
17. Lucki I, The forced swimming test as a model for core and component behavioral effects of antidepressant drugs, Behav Pharmacol, 8 (1997) 523.
18. Porsolt R D, Bertin A & Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants, Arch. Int. Pharmacodyn Ther, 229 (1977) 327.
19. Steru L, Chermat R, Thierry B & Simon P, The tail suspension test: a new method for screening antidepressant drugs, Psychopharmacology, 85 (1985) 367.
20. Thierry B, Steru L, Simon P & Porsolt R D, The tail suspension test: ethical considerations, Psychopharmacol, 90 (1986) 284.
21. Devadoss T, Pandey D K, Mahesh R & Yadav S K, Effect of acute and chronic treatment with QCF-3(4-benzylpiperazin-1-yl)(quinoxalin-2-yl)methanone, a novel 5-HT3 receptor antagonist, in animal models of depression, Pharmacol Rep, 62 (2010) 245.
22. Kelly J P, Wyrnn A S & Leonard B E, The olfactory bulbectomized rat as a model of depression: an update, Pharmacol Ther, 74 (1997) 299.
23. Mahesh R, Bhatt S, Pandey D K & Gautam B, Antidepressant like Effect of Pimozide in Acute and Chronic Animal Models of Depression, Indian J Pharm Edu Res, 45 (2011) 46.
24. Paton W D M & Zar A M, The origin of acetylcholine released from guinea-pig intestine and longitudinal muscle strips, J Physiol, 194 (1968) 13.
25. MacKay D, How should values of pA2 and affinity constants for pharmacological competitive antagonists be estimated, J Pharm Pharmacol, 30 (1978) 312.
26. Boissier J R & Simon P, Action de la caféine sur la motilite spontanee de la souris, Arch Int Pharmacodyn Ther, 158 (1965) 212.
27. Ripoll N, David D J, Dailly E, Hascoet M & Bourin M, effects in various mice strains in the tail suspension test, Behav Brain Res, 143 (2003) 193.
28. Englert L F, Ho B T & Taylor D, The effects of. (-)-delta9- tetrahydrocannabinol on reserpine- induced hypothermia in rats, Br J Pharmacol, 49 (1973) 243.
29. Rajkumar R & Mahesh R, The auspicious role of the 5-HT3 receptor in depression: A probable neuronal target, J Psychopharmacol, 24 (2010)455.
30. Simpson K H, Murphy P, Colthup P V & Whelan P, Concentration of ondansetron in cerebrospinal fluid following oral dosing in volunteers, Psychopharmacology (Berl), 109 (1992) 497.
31. Wolf H, Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists, Scand J Rheumatol Suppl, 113 (2000) 37.
32. Sheehan M, Wong H R & Hake PW, Parthenolide, an inhibitor of the nuclear factor-_B pathway, ameliorates cardiovascular derangement and outcome in endotoxic shock in rodents, Mol Pharmacol, 61(2002) 953.
33. Hoomissen V J, Kunrath J, Dentlinger R, Lafrenz A, Krause M & Azar A, Cognitive and locomotor/exploratory behavior after chronic exercise in the olfactory bulbectomy animal model of depression, Behav Brain Res, 222 (2011) 106.